In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.
Try Cornbread Hemp's new USDA-certified organic THC gummy. It's the first hemp THC gummy of…
Register to vote today to make your voice heard. The post Cannabis voter guide to…
We've all heard it before: smoke weed, and you'll become a lazy, unmotivated bum. The…
New THC+CBC Mood Mints from Rare Cannabinoid Company bring on mood-boosting effects quickly thanks to…
Pioneering research from Columbia University in New York suggests that psilocybin, the key component in…
A groundbreaking new study, funded by the Centers for Disease Control and Prevention, suggests exactly…